Initial 24-week data from a study of patients with psoriatic arthritis (PsA) show that treatment with guselkumab improved symptoms and resulted in a higher ACR20 response than placebo in patients who could not tolerate, or did not respond to, treatment with a tumor necrosis factor inhibitor (TNFi).
Reuters)—Severe COVID-19 may trick the immune system into producing autoantibodies that have the potential to eventually attack healthy tissue and cause inflammatory diseases, researchers warned in a paper published in Nature Communications.1 They found autoantibodies in blood samples from roughly 50% of the 147 COVID-19 patients they studied, but in fewer than 15% of 41…
Increased cardiovascular (CV) risk in patients with rheumatic disease is old news. Over the past decade, a multitude of studies have demonstrated elevated CV risk in a variety of conditions: systemic lupus erythematosus, rheumatoid arthritis and psoriatic arthritis (PsA), to name a few. The risk in patients with rheumatic disease seems to be linked to…
Bechman et al. set out to describe the frequency and predictors of nonserious infections and compare incidence rates across biologic DMARDs. They found all bDMARDs are associated with a greater risk of nonserious infection, with differences observed between agents. Although unmeasured confounding must be considered, the magnitude of effect is large.
Contraception, disease control, family planning and managing life with an infant—five experts addressed these concerns and more for patients with rheumatic disease during a special online webinar.
Seeing the challenges her rural patients faced in accessing specialty care, Amanda Schnell, MD, was inspired to make advocacy an integral part of her work at the University of Alabama at Birmingham.
The FDA has granted a seven-year marketing exclusivity for Octagam 10%, a 10% solution of a human intravenous immunoglobulin (IVIG) that treats adults with dermatomyositis.
Rheumatology leaders are encouraged by continued implementation of E/M coding changes, telehealth flexibilities and rheumatology-specific MIPS Value Pathway, but have concerns regarding conversion factor reductions and the CMS EHR interoperability and digital quality measures proposal.
In this third article in the series, we talk with Philip Seo, MD, MHS, about eosinophilic granulomatosis with polyangiitis (EGPA).
In 2015, the Department of Immunology at the University College London (UCL) rented a room above the King & Queen pub in London for a seminar series. Among the speakers was David Isenberg, MD, FRCP (Fellow of the Royal College of Physicians), FAMS (Fellow of the Academy of Medical Sciences), who still serves as UCL’s academic…